In one breath
PTC Therapeutics spent the better part of a decade burning cash on a pipeline that mostly disappointed. Then, in the twelve months through the fiscal year ended December 2025, it posted a 39% net margin and earned more than seven dollars per share. The stock trades at a price-to-sales ratio of 3.4, below its own decade median of 5.2, meaning the market is paying less per dollar of PTC’s sales today than it did during most of the years when the company was losing money. Those two facts sit in tension, and examining what explains the gap is the analytical task of this article.
The company that cried wolf, and then wasn’t
For most of its public life, PTC Therapeutics was a story stock: a rare-disease biotech with a compelling scientific pitch and a habit of spending more than it earned. For several years running through 2024, the losses were substantial. The Agilis Biotherapeutics acquisition in August 2018, which brought gene therapy programs into the fold for roughly $200 million upfront, looked expensive for years before it produced anything.
Then Sephience arrived. The FDA approved sepiapterin, PTC’s treatment for a rare metabolic disorder called phenylketonuria (PKU, a condition where the body cannot process a common amino acid, causing toxic buildup), on July 28, 2025. That single approval is the hinge on which the whole financial story turns.
What the margin actually says
Gross margin is what’s left of each dollar of sales after the direct cost of making and delivering the product. A software company might keep 70 cents. A typical drug manufacturer keeps 60 to 70 cents. PTC kept roughly 95 cents in the quarter ended June 30, 2026. That figure is not a rounding error. It reflects a business where the incremental cost of serving one more patient is nearly zero, because most of the revenue now flows from royalties and from a drug whose manufacturing costs are modest relative to its price.
The operating expense side is where the tension lives. PTC guided for a combined R&D and selling expense envelope that consumes most of the gross profit, per the Q2 2026 earnings release. Against full-year revenue guidance of $1.18 billion to $1.28 billion, the company expects to reach cash-flow breakeven for the full year, not to print the kind of margins the Q2 number might suggest in isolation. The strong FY2025 net margin was partly a function of a large income event early in the year; the quarterly picture is more volatile.
Sephience’s ramp, and what it needs to sustain
Sephience generated $124.6 million in its first full commercial quarter and $151.3 million in Q2 2026, a sequential gain of about 21%, per the June 2026 10-Q. For context, Translarna, which has been on the European market since 2014, brought in a fraction of that in the same quarter. Sephience is already more than three times the size of PTC’s oldest commercial product, less than a year after launch.
The risk embedded in that ramp is concentration. If Sephience is the engine, then anything that slows patient uptake, triggers a coverage dispute with insurers, or invites a competing therapy changes the math materially. PKU is rare, which means the addressable pool of patients is finite. The company has not disclosed how far through that pool it believes it has penetrated, so the data cannot tell us how much runway the ramp has left.
The pipeline bet the price is not paying for
Beyond the commercial products, PTC carries two late-stage programs that analysts cite as potential value drivers. Votoplam, a Huntington’s disease candidate, showed dose-dependent slowing of disease progression in a 24-month interim analysis reported in April 2026. Novartis, which licensed the drug, started the global Phase 3 INVEST-HD study in March 2026, triggering a milestone payment to PTC. Cantor Fitzgerald published a valuation estimate of $130 in August 2026, attributing a significant portion of that figure to the Votoplam program; the assumptions and methodology behind that estimate are available at the linked source for readers who wish to evaluate them independently. Whether those assumptions hold depends on Phase 3 outcomes and regulatory timing that remain uncertain.
Vatiquinone, PTC’s Friedreich’s ataxia candidate, is a harder story. The FDA asked for an additional study before it would consider a new drug application, and that open-label registration study, enrolling patients aged 7 to 21, is slated to begin in Q3 2026. A regulatory detour of that kind adds time and cost, and the outcome of the new study is genuinely uncertain. The data cannot tell us whether this program succeeds; it can only confirm that the path is longer than PTC originally planned.
The balance sheet after the refinancing
In June 2026, PTC issued $550 million in new convertible notes due in 2031 and used the proceeds to retire most of its notes that were coming due later that year, per the 8-K filed at the time. Think of it as rolling a credit card balance onto a new card with a five-year grace period. The company also carries a multi-billion-dollar liability tied to a royalty monetization deal, a structure where PTC sold the right to future Evrysdi royalties in exchange for cash upfront. That liability sits alongside a roughly equivalent cash and securities cushion, so the net picture is less alarming than the gross number suggests, but it is not a clean balance sheet.
Reading the numbers
- FY2025 net margin: 39.4%. The net margin is what’s left of each dollar of sales after every cost, tax, and interest payment. A 39% net margin means PTC kept about 39 cents of every revenue dollar last year. For comparison, the company was losing money as recently as FY2024. The swing reflects Sephience’s launch and a large income event in Q1 2025. A household analogy: imagine a small business that spent more than a dollar for every dollar it brought in one year, then suddenly kept nearly 40 cents of every dollar the next. That kind of reversal is rare and worth examining closely.
- Q2 2026 gross margin: ~94.5%. Calculated from the June 2026 10-Q: $361 million in revenue minus $19.9 million in cost of sales. For every $100 a patient’s insurer pays for PTC’s products, roughly $5.50 covers the direct cost of making and delivering them. The rest flows toward R&D, overhead, and eventually profit. This is a structurally high-margin business, not a manufacturing-intensive one.
- P/S ratio: 3.4, against a decade median of 5.2 (21st percentile). The price-to-sales ratio is the price tag per dollar of annual revenue. At 3.4, the market is paying $3.40 for each dollar of PTC’s sales. During most of the past decade, when the company was losing money, investors paid $5.20 per dollar of sales. Our data shows the current reading sits in the bottom fifth of its own history. The analogy illustrates why the combination of a lower valuation multiple and improved profitability is analytically unusual and warrants scrutiny of the underlying drivers.
- P/E ratio: 8.6, against a decade median of 8.9 (33rd percentile). The price-to-earnings ratio is the price tag per dollar of annual profit. At 8.6, investors are paying $8.60 for each dollar PTC earns. The decade median is $8.90. The gap is small, but the direction is notable: the market is pricing the earnings almost exactly at historical norms, even though those earnings only just appeared. Whether that reflects appropriate caution about their durability, or a lag in recognition, is the open question.
Sources
- 10-Q for quarter ended June 30, 2026 (SEC EDGAR)
- 10-K for fiscal year ended December 31, 2025 (SEC EDGAR)
- PTC Therapeutics Q2 2026 earnings release (PR Newswire)
- 8-K: June 2026 convertible notes refinancing (StockTitan)
- Sephience FDA approval history (Drugs.com)
- Votoplam PIVOT-HD interim results (NeurologyLive)
- Analyst valuation estimates for PTCT (Benzinga)
- Agilis Biotherapeutics acquisition (BioSpace)
